Anadis in-licenses GastroGard-R

Australian biopharmaceutical firm Anadis has in-licen;sed GastroGard-R, an all-natural, orally-administered formulation containing specific antibodies proven to reduce rotavirus virus diarrhea in young children.

The license allows Anadis to exclusively supply humanitarian agencies worldwide as well as to enter large national markets including India, Korea, Indonesia and Australia, with other countries expected to be added based on demand. GastroGard-R is positioned to complement global rotavirus virus vaccine initiatives and reduce overall morbidity and mortality from this terrible disease. The announcement was made at the Partnering for Global Health Forum 2008 being held in Washington DC, USA.